Cargando…

Examining the unit costs of COVID-19 vaccine delivery in Kenya

BACKGROUND: Vaccines are considered the path out of the COVID-19 pandemic. The government of Kenya is implementing a phased strategy to vaccinate the Kenyan population, initially targeting populations at high risk of severe disease and infection. We estimated the financial and economic unit costs of...

Descripción completa

Detalles Bibliográficos
Autores principales: Orangi, Stacey, Kairu, Angela, Ngatia, Anthony, Ojal, John, Barasa, Edwine
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8978155/
https://www.ncbi.nlm.nih.gov/pubmed/35379227
http://dx.doi.org/10.1186/s12913-022-07864-z
_version_ 1784680919656824832
author Orangi, Stacey
Kairu, Angela
Ngatia, Anthony
Ojal, John
Barasa, Edwine
author_facet Orangi, Stacey
Kairu, Angela
Ngatia, Anthony
Ojal, John
Barasa, Edwine
author_sort Orangi, Stacey
collection PubMed
description BACKGROUND: Vaccines are considered the path out of the COVID-19 pandemic. The government of Kenya is implementing a phased strategy to vaccinate the Kenyan population, initially targeting populations at high risk of severe disease and infection. We estimated the financial and economic unit costs of procuring and delivering the COVID-19 vaccine in Kenya across various vaccination strategies. METHODS: We used an activity-based costing approach to estimate the incremental costs of COVID-19 vaccine delivery, from a health systems perspective. Document reviews and key informant interviews(n = 12) were done to inform the activities, assumptions and the resources required. Unit prices were derived from document reviews or from market prices. Both financial and economic vaccine procurement costs per person vaccinated with 2-doses, and the vaccine delivery costs per person vaccinated with 2-doses were estimated and reported in 2021USD. RESULTS: The financial costs of vaccine procurement per person vaccinated with 2-doses ranged from $2.89-$13.09 in the 30% and 100% coverage levels respectively, however, the economic cost was $17.34 across all strategies. Financial vaccine delivery costs per person vaccinated with 2-doses, ranged from $4.28-$3.29 in the 30% and 100% coverage strategies: While the economic delivery costs were two to three times higher than the financial costs. The total procurement and delivery costs per person vaccinated with 2-doses ranged from $7.34-$16.47 for the financial costs and $29.7-$24.68 for the economic costs for the 30% and 100% coverage respectively. With the exception of procurement costs, the main cost driver of financial and economic delivery costs was supply chain costs (47–59%) and advocacy, communication and social mobilization (29–35%) respectively. CONCLUSION: This analysis presents cost estimates that can be used to inform local policy and may further inform parameters used in cost-effectiveness models. The results could potentially be adapted and adjusted to country-specific assumptions to enhance applicability in similar low-and middle-income settings.
format Online
Article
Text
id pubmed-8978155
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-89781552022-04-04 Examining the unit costs of COVID-19 vaccine delivery in Kenya Orangi, Stacey Kairu, Angela Ngatia, Anthony Ojal, John Barasa, Edwine BMC Health Serv Res Research BACKGROUND: Vaccines are considered the path out of the COVID-19 pandemic. The government of Kenya is implementing a phased strategy to vaccinate the Kenyan population, initially targeting populations at high risk of severe disease and infection. We estimated the financial and economic unit costs of procuring and delivering the COVID-19 vaccine in Kenya across various vaccination strategies. METHODS: We used an activity-based costing approach to estimate the incremental costs of COVID-19 vaccine delivery, from a health systems perspective. Document reviews and key informant interviews(n = 12) were done to inform the activities, assumptions and the resources required. Unit prices were derived from document reviews or from market prices. Both financial and economic vaccine procurement costs per person vaccinated with 2-doses, and the vaccine delivery costs per person vaccinated with 2-doses were estimated and reported in 2021USD. RESULTS: The financial costs of vaccine procurement per person vaccinated with 2-doses ranged from $2.89-$13.09 in the 30% and 100% coverage levels respectively, however, the economic cost was $17.34 across all strategies. Financial vaccine delivery costs per person vaccinated with 2-doses, ranged from $4.28-$3.29 in the 30% and 100% coverage strategies: While the economic delivery costs were two to three times higher than the financial costs. The total procurement and delivery costs per person vaccinated with 2-doses ranged from $7.34-$16.47 for the financial costs and $29.7-$24.68 for the economic costs for the 30% and 100% coverage respectively. With the exception of procurement costs, the main cost driver of financial and economic delivery costs was supply chain costs (47–59%) and advocacy, communication and social mobilization (29–35%) respectively. CONCLUSION: This analysis presents cost estimates that can be used to inform local policy and may further inform parameters used in cost-effectiveness models. The results could potentially be adapted and adjusted to country-specific assumptions to enhance applicability in similar low-and middle-income settings. BioMed Central 2022-04-04 /pmc/articles/PMC8978155/ /pubmed/35379227 http://dx.doi.org/10.1186/s12913-022-07864-z Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research
Orangi, Stacey
Kairu, Angela
Ngatia, Anthony
Ojal, John
Barasa, Edwine
Examining the unit costs of COVID-19 vaccine delivery in Kenya
title Examining the unit costs of COVID-19 vaccine delivery in Kenya
title_full Examining the unit costs of COVID-19 vaccine delivery in Kenya
title_fullStr Examining the unit costs of COVID-19 vaccine delivery in Kenya
title_full_unstemmed Examining the unit costs of COVID-19 vaccine delivery in Kenya
title_short Examining the unit costs of COVID-19 vaccine delivery in Kenya
title_sort examining the unit costs of covid-19 vaccine delivery in kenya
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8978155/
https://www.ncbi.nlm.nih.gov/pubmed/35379227
http://dx.doi.org/10.1186/s12913-022-07864-z
work_keys_str_mv AT orangistacey examiningtheunitcostsofcovid19vaccinedeliveryinkenya
AT kairuangela examiningtheunitcostsofcovid19vaccinedeliveryinkenya
AT ngatiaanthony examiningtheunitcostsofcovid19vaccinedeliveryinkenya
AT ojaljohn examiningtheunitcostsofcovid19vaccinedeliveryinkenya
AT barasaedwine examiningtheunitcostsofcovid19vaccinedeliveryinkenya